{"id":"W4399218268","doi":"10.1200/jco.24.00733","title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Centro de Investigación Biomédica en Red de Cáncer; European Commission; National Institute on Minority Health and Health Disparities; Comunidad de Madrid; Instituto de Salud Carlos III; Gilead Sciences","keywords":"Medicine; Docetaxel; Open label; Lung cancer; Oncology; Randomized controlled trial; Internal medicine; Phases of clinical research; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001740085,0.001302575,0.002531471,0.000371807,0.0002423818,0.001011211,0.000893203,0.001232738,0.0030262],"category_scores_gemma":[0.001451774,0.0004752582,0.001358389,0.0003297039,0.001038326,0.0007881138,0.000338477,0.002691968,0.0005736707],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007080936,"about_ca_system_score_gemma":0.0008580442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007010815,"about_ca_topic_score_gemma":0.002672923,"domain_scores_codex":[0.9994588,0.0003319873,0.00002420573,0.00005815841,0.00004972489,0.00007717813],"domain_scores_gemma":[0.9991572,0.0002766475,0.0001656808,0.00005875993,0.00005011209,0.0002916293],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9465433,0.01655971,0.001483129,0.0007229459,0.0008523748,0.00005790938,0.00007465255,0.0009051275,0.005200304,0.0001893797,0.001255878,0.02615532],"study_design_scores_gemma":[0.8192568,0.1737685,0.003263959,0.00004301033,0.0004378869,0.0000949788,0.00004684466,0.0008496244,0.0008431195,0.0001681985,0.001207632,0.00001929164],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936817,0.002391776,0.000298833,0.0002540922,0.0002890668,0.001237674,0.0005364744,0.00005041162,0.001259974],"genre_scores_gemma":[0.9926741,0.001708215,0.0006002287,0.0006437826,0.0003151259,0.00121772,0.0008829411,0.00001861458,0.00193927],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0030262,"threshold_uncertainty_score":0.01012361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1543476448279368,"score_gpt":0.5628618517731004,"score_spread":0.4085142069451637,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}